Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib

被引：0
|
作者：
Zwierenga, F. [1 ]
Muntinghe-Wagenaar, B. [1 ]
Rozendal, P. [1 ]
van der Leest, P. [1 ]
Schuuring, E. [1 ]
van der Wekken, A. J. [1 ]
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
ctDNA; EGFR exon 20; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.06D.02
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [21] Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer
    Isobe, Kazutoshi
    Yoshizawa, Takahiro
    Sekiya, Muneyuki
    Miyoshi, Shion
    Nakamura, Yasuhiko
    Urabe, Naohisa
    Isshiki, Takuma
    Sakamoto, Susumu
    Takai, Yujiro
    Tomida, Taichiro
    Adachi-Akahane, Satomi
    Iyoda, Akira
    Homma, Sakae
    Kishi, Kazuma
    RESPIRATORY INVESTIGATION, 2021, 59 (04) : 535 - 544
  • [22] Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer
    Isobe, K.
    Kobayashi, H.
    Isshiki, T.
    Sakamoto, S.
    Takai, Y.
    Tomida, T.
    Adachi-Akahane, S.
    Kishi, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S417 - S418
  • [23] Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC
    dall'Olio, F. G.
    Vasseur, D.
    Mamann, A.
    Garcia, C. A.
    Beshiri, K.
    Marinello, A.
    Tagliamento, M.
    Ghigna, M. R.
    Aldea, M.
    Planchard, D.
    Pasquina, L.
    Barlesi, F.
    Italiano, A.
    Madison, R.
    Oxnard, G.
    Besse, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1192 - S1193
  • [24] Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
    Santos, Edgardo
    Kaplan, Barry
    Kirshner, Eli
    Croft, Elisabeth
    Sequist, Lecia
    Burke, Lea
    Munley, Jiefen
    Oxnard, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1237 - S1237
  • [25] Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study
    Peled, N.
    Rotem, O.
    Rozenblum, A.
    Nechushtan, H.
    Chen, L.
    Dudnik, E.
    Zer, A.
    Yust-Katz, S.
    Shelef, I.
    Roisman, L.
    Inbar, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S665 - S666
  • [26] Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients
    Zhang, Hao
    He, Bin
    Cui, Jun
    Zhao, Mingzhang
    Zhang, Zengwang
    CANCER BIOMARKERS, 2018, 23 (03) : 427 - 436
  • [27] Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC
    Bordi, P.
    Del Re, M.
    Danesi, R.
    Tiseo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S57 - S57
  • [28] The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
    Szpechcinski, Adam
    Bryl, Maciej
    Czyzewicz, Grzegorz
    Wojda, Emil
    Swiniuch, Daria
    Szwiec, Marek
    Ramlau, Rodryg
    Sliwinski, Pawel
    Barinow-Wojewodzki, Aleksander
    Chorostowska-Wynimko, Joanna
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [29] Osimertinib for EGFR-Positive NSCLC Patients with Leptomeningeal Metastases Harboring T790M-Positive or T790M-Negative Mutations
    Xu, H.
    Zhang, Y.
    Kong, J.
    Yang, G.
    Yang, L.
    Liu, S.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S612 - S613
  • [30] Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
    Van Veggel, B.
    Van der Wekken, A.
    Hashemi, S.
    Cornelissen, R.
    Monkhorst, K.
    Heideman, D.
    Radonic, T.
    Schuuring, E.
    Smit, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S815 - S815
12345